Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
19.06
+0.25 (1.33%)
At close: Mar 9, 2026, 4:00 PM EDT
19.07
+0.01 (0.05%)
After-hours: Mar 9, 2026, 5:00 PM EDT
Aktis Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aktis Oncology stock have an average target of 30, which predicts a 57.40% increase from the current stock price of 19.06.
Price Target: $30 (+57.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aktis Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +57.40% | Mar 9, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $30 | Buy | Initiates | $30 | +57.40% | Feb 3, 2026 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $2 → $1 | Buy → Hold | Downgrades | $2 → $1 | -94.75% | Jan 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $6 → $3 | Buy | Maintains | $6 → $3 | -84.26% | Sep 7, 2023 |
| B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $9.25 → $1.75 | Strong Buy → Hold | Downgrades | $9.25 → $1.75 | -90.82% | Sep 7, 2023 |
Financial Forecast
Revenue This Year
7.41M
from 1.49M
Increased by 398.52%
Revenue Next Year
20.86M
from 7.41M
Increased by 181.38%
EPS This Year
-3.25
from -62.46
EPS Next Year
-1.28
from -3.25
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.5M | 52.5M | |
| Avg | 7.4M | 20.9M | |
| Low | 4.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 606.1% | 608.2% | |
| Avg | 398.5% | 181.4% | |
| Low | 229.5% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.49 | -0.84 | |
| Avg | -3.25 | -1.28 | |
| Low | -7.10 | -1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.